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Abstract: Sphingolipids and in particular ceramide have been shown to be critically involved in the response to many 
receptor-mediated, but also receptor-independent, mainly stress stimuli. Recent studies demonstrate that ceramide plays 
an important role in the pathogenesis of cystic fibrosis, a hereditary metabolic disorder caused by mutations of the Cystic 
Fibrosis Transmembrane Conductance Regulator. Patients with cystic fibrosis suffer from chronic pulmonary 
inflammation and microbial lung infections, in particular with Pseudomonas aeruginosa. Chronic pulmonary 
inflammation in these patients seems to be the initial pathophysiological event. Inflammation may finally result in the 
high infection susceptibility of these patients, fibrosis and loss of lung function. Recent studies demonstrated that 
ceramide accumulates in lungs of cystic fibrosis mice and causes age-dependent pulmonary inflammation as indicated by 
accumulation of neutrophils and macrophages in the lung and increased pulmonary concentrations of Interleukins 1 and 8, 
death of bronchial epithelial cells, deposition of DNA in bronchi and high susceptibility to Pseudomonas aeruginosa 
infections. Genetic or pharmacological inhibition of the acid sphingomyelinase blocks excessive ceramide production in 
lungs of cystic fibrosis mice and corrects pathological lung findings. First clinical studies confirm that inhibition of the 
acid sphingomyelinase with small molecules might be a novel strategy to treat patients with cystic fibrosis. 
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CYSTIC FIBROSIS 
  Cystic fibrosis (CF) is caused by mutations of the Cystic 
Fibrosis Transmembrane Conductance Regulator (CFTR) [1-
3] and constitutes with 1 case per 2500 births the most 
common autosomal recessive disorder in the EU and the 
USA. Approximately 40 000 children and young adults are 
affected in the EU. The genetic defect of the CFTR-molecule 
results in several clinical symptoms, in particular pulmonary 
and gastrointestinal problems. Gastrointestinal symptoms 
include a defective secretion of pancreatic enzymes and 
alterations of the liver, pulmonary problems are in particular 
recurrent and chronic infections with Pseudomonas 
aeruginosa (P. aeruginosa) and Burkholderia cepacia, but 
also  Staphylococcus aureus and Haemophilus influenzae. 
The cause for the high sensitivity of cystic fibrosis patients 
to develop these pulmonary infections is unknown. 
 P.  aeruginosa infections are most important in patients 
with cystic fibrosis. Once past early childhood a very high 
percentage of patients with cystic fibrosis suffers from 
recurrent and finally chronic P. aeruginosa pneumonia [4]. 
More than 80% of adult patients with cystic fibrosis are 
infected with the pathogen and chronic P. aeruginosa lung 
infections are the leading cause of morbidity and mortality in 
cystic fibrosis [4]. 
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INFLAMMATION IN CYSTIC FIBROSIS 
  Since CFTR exhibits a chloride channel activity, it was 
speculated that water absorption in the mucus present on 
epithelial cells of the respiratory tract is altered, which may 
result in a reduced mucociliary clearance and a reduced 
ability to eliminate P. aeruginosa [5, 6]. The increased 
viscosity of the mucus may also affect the ability of 
neutrophils to migrate to and kill bacteria in the respiratory 
tract. However, although in vitro experiments suggested the 
concept of reduced mucociliary clearance in cystic fibrosis 
[5],  in vivo studies on cystic fibrosis patients failed to 
demonstrate a significant and uniform reduction of the 
mucociliary clearance in these individuals [6]. 
  A defect in the chloride channel function of CFTR may 
also result in changes of the ion concentration in the mucus. 
The altered concentration of ions may then impair the 
function of defensins and other anti-microbial peptides and, 
thus, reduce the elimination of P. aeruginosa in the lung [7]. 
However, at present it is unknown whether the defect of 
CFTR really results in hypertonic salt concentrations on the 
respiratory epithelium in vivo and, thus, dysfunction of 
antimicrobial peptides. 
  Several studies suggest a defect of vesicular pH-
regulation in cystic fibrosis. Barasch et al. were first to show 
that CFTR participates in pH control of trans-Golgi vesicles 
[8]. A defect of CFTR resulted in alkalinization of these 
vesicles. More recently, it was shown that Cftr contributes to 
acidification of phagolysosomes in macrophages [9]. Cftr 
seems to control the influx of chloride ions into lysosomes, 
which serve as counterions for protons pumped into   
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phagolysosomes by the lysosomal V-type H
+-ATPase. 
Deficiency of Cftr limits accumulation of protons in 
phagolysosomes and, thus, acidification of these vesicles to 
pH values less than 5-6. The defective acidification of 
phagolysosomes, in particular in Cftr-deficient alveolar 
macrophages, blocks the bactericidal activities of lysosomal 
enzymes and, thus, the ability of macrophages to kill 
internalized bacteria [9]. Recent studies from our laboratory 
on freshly isolated epithelial cells from Cftr-deficient mice 
confirmed previous studies by Di et al. that Cftr controls the 
pH of at least some vesicle populations in these cells [10]. 
Further unpublished studies from our group using freshly 
isolated macrophages from Cftr-deficient mice demonstrate 
that Cftr controls the pH in a specific vesicle population, 
most likely secretory lysosomes, already in non-infected 
cells, while the pH in endocytotic vesicles is independent of 
Cftr. The specific role of Cftr in the control of the pH of a 
distinct subset of vesicles also explains findings of other 
groups [11, 12] that reported that Cftr-deficiency does not 
control lysosomal pH. These studies investigated the pH in 
vesicles employing zymosan-conjugates containing fluore-
scein and tetramethylrhodamine-dextran and, thus, these 
studies report the pH in vesicles that were generated upon 
endocytosis of these dyes [11, 12]. This suggests that Cftr 
only determines the pH in distinct vesicle populations, most 
likely pre-lysosomes, secretory lysosomes and lysosomes 
that are not part of the endocytosis machinery. 
 Pier  et al. demonstrated a defect of the innate immune 
function of epithelial cells in the respiratory tract of cystic 
fibrosis mice. They showed that the lipopolysaccharide 
(LPS)-molecule of P. aeruginosa binds to a short amino acid 
sequence in CFTR (AA 103-117) [13]. This interaction 
mediates internalisation of P. aeruginosa into lung epithelial 
cells. Deficiency of Cftr or blockade of the binding sequence 
prevents P. aeruginosa internalisation [13]. Bacterial intern-
alisation correlated with the defense against P. aeruginosa in 
lungs of infected mice, although the causative role of the 
internalisation defect for the high sensitivity of these mice to 
develop  P. aeruginosa infections remains to be demon-
strated. Further studies suggested that internalisation of P. 
aeruginosa is also mediated by other mechanisms. The 
uptake mechanisms also seem to depend on the bacterial 
strain, since rough, mucoid strains of P. aeruginosa are able 
to enter epithelial cells independently of CFTR expression 
[14]. 
  Studies by several groups demonstrate that P. aeruginosa 
triggers cell death of Cftr-positive epithelial cells in vitro as 
well as in a focal pattern in bronchial epithelial cells in the 
lung. Apoptosis is mediated by an activation of the 
endogenous CD95 receptor/CD95 ligand-system within 
distinct membrane domains in epithelial cells upon infection 
with  P. aeruginosa [15-18].  In vivo studies indicate that 
stimulation of CD95 and, thus, presumably induction of 
apoptosis in epithelial cells is central for a coordinated 
defense against pulmonary P. aeruginosa infections. It might 
be possible that the induction of apoptosis in epithelial cells 
modulates the local immune response to the pathogen and 
prevents an over-exaggerated release of cytokines [19, 20]. 
Studies from Kumar et al. on two independent CF patient 
cohorts demonstrate that allelic variants within intron 2 of 
the CD95 gene modulate the manifestation of CF disease 
further suggesting a role of CD95-mediated signalling/ 
apoptosis in cystic fibrosis [21]. 
  Several studies in the recent years suggest an imbalance 
between pro-inflammatory and anti-inflammatory cytokines 
in the airways of cystic fibrosis patients as one of the leading 
causes to result in destruction of the lung and the high 
susceptibility of these patients to infections with P. 
aeruginosa. It was demonstrated that cells lacking functional 
CFTR secrete increased amounts of Interleukin (IL)-1, IL-
8/KC, TNF-alpha and Mip-2 upon infection with P. 
aeruginosa compared to control cells [22-25]. IL-8 is already 
increased in the trachea of non-infected Cftr-deficient mice 
[23], while the synthesis of anti-inflammatory cytokines, in 
particular IL-10 [25], has been shown to be reduced in Cftr-
deficient mice under basal conditions as well as after 
infection with P. aeruginosa. The increased release of pro-
inflammatory cytokines from CFTR-deficient epithelial cells 
correlates with a constitutive activation of NFB in these 
cells [26, 27]. Several studies indicated that at least some 
mutations of Cftr result in accumulation of the mutated 
protein in CF cells, which triggers endoplasmic reticulum 
stress and finally increased NFB-activity [28]. In addition, 
a recent study indicated that Cftr must be present in 
membrane rafts to suppress activation of NFB in CF cells 
[29] suggesting that Cftr controls several checkpoints of 
NFB-activity. 
CERAMIDE 
  The cell membrane contains sphingolipids, cholesterol 
and (glycero)phospholipids among other less abundant 
lipids. Sphingolipids consist of a hydrophobic ceramide 
moiety and a hydrophilic headgroup. Ceramide is composed 
of D-erythro-sphingosine and a fatty acid containing 2-28 
carbon atoms in the acyl chain that is connected via an amide 
ester bond [30]. Based on biophysical experiments deter-
mining the melting temperatures of lipids, Singer and 
Nicolson introduced the classical fluid mosaic model in 1972 
predicting free movement of proteins in the lipid bilayer 
[31]. However, this concept was revised in the last 10-15 
years and present concepts indicate the existence of distinct 
membrane domains [32, 33]. Sphingolipids interact with 
each other and with cholesterol molecules via hydrophilic 
interactions between the sphingolipid headgroups and the 
hydroxy group in the cholesterol molecule, respectively, and 
via hydrophobic van der Waal interactions between ceramide 
moieties and the sterol ring system [32-35]. The tight 
interactions of sphingolipids and cholesterol were suggested 
to promote the transition of membrane lipids into a liquid 
ordered status and the formation of very small distinct 
domains in the cell membrane, named rafts [32]. Rafts are 
proposed to be very small membrane domains enriched in 
sphingolipids and cholesterol that spontaneously separate 
from other phospholipids in the cell membrane [32-35]. 
Recent microscopy studies demonstrated rafts in cells and 
indicated a size of approximately 20 nm [35]. These 
experiments also suggest that rafts serve to sort proteins in 
the cell membrane and, thus, to contribute to a lateral 
organization of the cell membrane. 
  The generation of ceramide within rafts, but also 
independent of rafts, dramatically alters membrane proper-
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enriched membrane microdomains, which have the tendency 
to spontaneously fuse to large ceramide-enriched membrane 
domains [36-38]. The formation of ceramide-enriched 
membrane domains was shown to occur in cells after 
stimulation via a variety of stimuli including CD95 [39-41], 
CD40 [42], DR5 [43], FcRII [44], the PAF-receptor [45], 
but also after infection with P. aeruginosa [19], Neisseriae 
gonorrhoeae [46],  Rhinovirus [47], application of stress 
stimuli such as UV-light [48], cisplatin [49] or Cu
2+-
treatment [50]. The great variety of stimuli that trigger the 
formation of ceramide-enriched membrane platforms 
suggests that these membrane domains facilitate signal 
transduction, but are very likely not part of the specific 
signal transduction pathway elicited by the these stimuli. 
  We suggested that ceramide-enriched membrane domains 
serve to re-organize receptor molecules and intracellular 
signaling molecules in the cell membane [51], which permits 
the specific receptor to transmit its signal into the cell. 
Ceramide-enriched membrane domains exhibit very different 
biophysical properties than other parts of the plasma 
membrane resulting in preferential trapping of activated 
receptor molecules and/or signaling molecules in these 
domains. The trapping of proteins within ceramide-enriched 
membrane domains might be enhanced by a direct 
interaction of ceramide with proteins. However, at present 
the molecular details of receptor clustering and preferential 
sorting of molecules to ceramide-enriched membrane 
domains are unknown. It was shown that the transmembrane 
domain of CD40 is critically involved in trapping of the 
receptor to ceramide-enriched domains [52]. Thus, an 
alteration of the transmembrane domain upon binding of the 
ligand to its receptor may provide specificity for protein-
sorting into ceramide-enriched membrane domains. 
Clustering of receptors and associated signaling molecules 
may result in a density of receptors and signaling molecules, 
the spatial association of activated receptors with 
intracellular molecules, the exclusion of inhibitory enzymes 
and/or transactivation of intracellular enzymes. Thus, 
clustering might coordinate the spatial and temporal 
organization of the signalosome generated by a specific 
receptor. 
  In addition, ceramide has been shown to directly regulate 
several molecules including cathepsin D [53], phospholipase 
A2 [54], kinase suppressor of Ras [55], ceramide-activated 
protein serine-threonine phosphatases (CAPP) [56] and 
protein kinase C isoforms [57, 58]. Further, ceramide has 
been shown to regulate the activity of the potassium channel 
Kv1.3 and calcium release-activated calcium (CRAC) 
channels [59-60]. Ceramide inhibits the activity of these ion 
channels in the cell membrane [59-62]. At present it is 
unknown how ceramide affects the activity of ion channels, 
but it might be possible that ceramide alters ion channels by 
a direct interference or by the change of the lipid 
composition in the environment of the channel [62]. In 
addition, studies by Siskind and Columbini demonstrated 
that ceramide molecules form channels in the outer 
mitochondrial membrane, which might contribute to the 
induction of apoptosis [63]. 
  Many of these signalling molecules directly affected by 
ceramide are also good candidates to be involved in the 
regulation of inflammation by ceramide, for instance 
cathepsin D, phospholipase A2, kinase suppressor of Ras, 
Kv1.3 and calcium release-activated calcium channels. The 
role of ceramide in cystic fibrosis is described below. 
SPHINGOMYELINASES 
  Ceramide is generated by (i) sphingomyelinases [30, 64, 
65], (ii) by a de novo synthase pathway [30, 65], (iii) by a 
retrograde activity of the enzyme ceramidase that mediates 
the synthesis of ceramide from sphingosine [66], (iv) by the 
hydrolysis of complex glycosylated lipids [67] and (v) by 
hydrolysis of ceramide 1-phosphate [68]. Sphingomyelinases 
hydrolyse sphingomyelin to release ceramide. Sphingomye-
linases display peak activities depending on the pH and, 
thus, were named acid, neutral and alkaline sphingomye-
linase. Mammalian cells express one gene for the acid 
sphingomyelinase, which can be targeted to lysosomes or for 
secretion into secretory lysosomes depending on the glyco-
sylation pattern of the protein [69, 70]. Mammalian cells 
express at least two different neutral sphingomyelinases and 
one alkaline sphingomyelinase [65]. 
  The molecular mechanisms of the regulation of 
sphingomyelinases still require definition. The activity of 
neutral sphingomyelinases seems to be regulated by the 
redox balance in the cell [71]. However, further details of the 
stimulation of neutral sphingomyelinase are presently not 
known. The acid sphingomyelinase is activated by oxidation 
[43, 50, 72]. It is unknown whether the protein is directly 
oxidized in vivo or regulated via pathways that are redox-
sensitive. Scavengers of reactive oxygen intermediates 
prevent activation of the acid sphingomyelinase by stimuli 
such as DR5 or Cu
2+ [43, 50, 72]. In vitro studies by Qui et 
al. [72] on purified acid sphingomyelinase suggest a direct 
oxidation of the acid sphingomyelinase at cysteine residue 
629 with a subsequent copper-promoted dimerisation of the 
acid sphingomyelinase [72]. The oxidation of cysteine 629 
correlated with an activation of the enzyme in vitro. In 
addition, phosphorylation of the protein at serine 508 has 
been shown to activate the enzyme [73]. The enzyme is 
inhibited by inositol-phosphates [74, 75], although the 
physiological significance of these findings remains to be 
determined. 
  The acid sphingomyelinase has been shown to be 
activated within lysosomes or multilamellar bodies, 
respectively, for instance after cellular stimulation via TNF 
receptors [53]. Other receptors, for instance CD95 or DR5, 
or infections with P. aeruginosa trigger a translocation of the 
acid sphingomyelinase onto the extracellular leaflet [39, 40, 
43]. Translocation of the enzyme onto the outer leaflet of the 
cell membrane is very likely mediated by the fusion of 
vesicles, in particular secretory lysosomes that contain the 
enzyme [76], with the plasma membrane. The mobilisation 
of these vesicles and the fusion with the cell membrane 
occurs within seconds after cellular stimulation or infection, 
respectively. 
  Several studies [77-80] identified pharmacological 
inhibitors of the acid sphingomyelinase; the acid 
sphingomyelinase seems to interact with intra-lysosomal 
membranes, thereby being protected against proteolytic 
inactivation [77]. Weak bases such as amitriptyline diffuse 
into cells, are protonated in lysosomes and concentrated in 
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drugs are necessary but not sufficient to functionally inhibit 
the acid sphingomyelinase [80]. These drugs interfere with 
binding of the acid sphingomyelinase to the membrane, 
which results in a detachment of the acid sphingomyelinase 
and subsequent proteolytic degradation [77-80]. The 
lipophilic ring structures that are present in all acid 
sphingomyelinase inhibitors are embedded in the lysosomal 
membrane, while the cationic amino group linked through an 
aliphatic chain to the ring system of all acid 
sphingomyelinase inhibitors interferes with binding of the 
enzyme to the membrane finally resulting in detachment and 
subsequent proteolytic degradation in the lysosome [80]. 
Thus, weak bases are not attacking the active center of the 
acid sphingomyelinase, but functionally inhibit the acid 
sphingomyelinase. It should be noted that acid 
sphingomyelinase inhibitors usually act fast and for a 
prolonged time. 
CERAMIDE IN CYSTIC FIBROSIS 
  We have recently demonstrated that ceramide plays a 
critical role in the development of cystic fibrosis and the 
high sensitivity of Cftr-deficient mice to P. aeruginosa 
infections [11, 20]. Employing biochemical, fluorescence 
microscopy and mass spectrometry techniques, we revealed 
an accumulation of ceramide in lungs, in particular in 
epithelial cells of large and small bronchi, in different Cftr-
deficient mouse strains (Fig. 1). Of note, ceramide 
accumulates in these cells prior to any infection. Further, 
ceramide accumulates in the lungs of Cftr-deficient mice in 
an age-dependent manner, which seems to mimic the delayed 
onset of symptoms in humans. We suggested that an 
alteration of the pH particular in secretory lysosomes, pre-
lysosomes and/or lysosomes causes the accumulation of 
ceramide in Cftr-deficient cells (Fig. 2). Since the signalling 
pool of the acid sphingomyelinase seems to be 
predominantly localized to secretory lysosomes, we favour a 
primary accumulation of ceramide within these vesicles, 
although this hypothesis has yet to be proved. As described 
above Cftr-deficiency results in alkalinization of some, but 
not all, intracellular vesicles, in respiratory epithelial cells 
and macrophages. It should be noted that other vesicles, in 
particular endosomes, with a different pattern of ion channel 
expression than secretory lysosomes may not be alkalinized 
in  Cftr-deficient cells. Since the enzymes that control 
ceramide metabolism in acidic vesicles are pH-dependent, an 
alkalinization of these vesicles has a dramatic effect on 
ceramide concentrations; sphingomyelin is constitutively 
metabolized to ceramide by the acid sphingomyelinase and 
consumed to sphingosine by the activity of the acid 
ceramidase [30]. An increase of the pH from values around 
4.5 to pH 6.0 reduces the activity of the acid 
sphingomyelinase by only 30%, while the acid ceramidase 
is almost inactived at pH 6.0 [11]. The imbalance of the two 
enzymes activities with a relative over-activity of the acid 
sphingomyelinase may then result in an accumulation of 
ceramide. 
  Pulmonary ceramide accumulation was observed in two 
strains of Cftr-deficient mice [11]. Ceramide accumulation 
was also observed in ciliated nasal epithelial cells and lung 
specimens from transplant material from patients with cystic 
fibrosis [11]. This suggests that the mouse data also apply to  
 
individuals with cystic fibrosis. Partial genetic or pharmaco-
logical inhibition of the acid sphingomyelinase almost 
normalizes ceramide concentrations in lungs of Cftr-
deficient mice. Genetic inhibition of the acid sphingomye-
linase was achieved by crossing Cftr-deficient mice with 
acid sphingomyelinase deficient mice (Smpd1
-/- mice, Smpd1 
is the gene symbol for sphingomyelinase phosphodiesterase 
1, the systematic name for the acid sphingomyelinase) [11]. 
This resulted in mice deficient for Cftr and heterozygote for 
the acid sphingomyelinase in (Cftr
-/-/Smpd1
+/- mice) [11]. 
The activity of the acid sphingomyelinase in the lung of 
those mice was approximately 50% lower than in wild type 
mice [11]. Pharmacological inhibition of the acid sphingo-
myelinase was achieved by treatment of Cftr-deficient mice 
with the functional acid sphingomyelinase inhibitor amitri-
ptyline [11]. 
  Increased ceramide concentrations in bronchial epithelial 
cells and lung macrophages of Cftr-deficient mice trigger 
several hallmarks of cystic fibrosis, i.e. death of respiratory 
epithelial cells and deposition of DNA in bronchi, chronic 
pulmonary inflammation and high susceptibility of Cftr-
deficient mice to develop pulmonary P. aeruginosa 
infections (Fig. 2). 
  The causative role of ceramide for increased cell death in 
the respiratory tract of Cftr-deficient mice is established by 
pharmacological and genetic inhibition of the acid 
sphingomyelinase in Cftr-deficient mice. Inhibition of 
ceramide accumulation in Cftr-deficient mice normalizes the 
increased death rates of bronchial epithelial cells in these 
mice. Ceramide has been demonstrated to mediate apoptosis 
by CD95 and DR5. Ceramide also activates cathepsin D in 
lysosomes to initiate the mitochondrial death pathway upon 
TNF-receptor activation [39, 43, 53]. However, at present it 
is unknown whether any death receptors or cathepsin D are 
involved in cell death observed in the airways of Cftr-
deficient mice. Many studies have implicated short chain 
ceramides as triggers of apoptosis, however, they do not 
reflect the functions of physiological, long chain ceramides. 
Molecular mechanisms that mediate cell death by increased 
concentrations of cellular, long chain ceramides are largely 
unknown. Studies by R. Kolesnick et al. demonstrated the 
generation of mitochondrial ceramides upon irradiation, 
which triggers mitochondrial changes resulting in apoptosis 
[81]. However, it has to be determined whether a similar 
mechanism applies to effects of chronically accumulated 
ceramide in Cftr-deficient cells. Further, it remains to be 
defined which type of cell death, i.e. apoptosis, necrosis or 
any atypical form of cell death, is induced by ceramide in 
airway epithelial cells of Cftr-deficient mice. Finally, the 
signalling pathways that mediate ceramide-induced cell 
death in the respiratory tract of cystic fibrosis mice remain to 
be determined. 
  In any case, increased cell death in the respiratory tract of 
Cftr-deficient mice results in deposition of extracellular 
DNA on epithelial cells [11]. These DNA deposits may 
facilitate bacterial adherence in the respiratory tract and, 
thus, are critical for the development of the high infection 
susceptibility of cystic fibrosis mice to P. aeruginosa 
infections. This is supported by the findings that   
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Fig. (1). Accumulation of ceramide in bronchial epithelial cells of Cftr-deficient mice. The figure demonstrates the accumulation of 
ceramide in bronchial epithelial cells of Cftr-deficient mice. Lungs from wildtype (wt) or Cftr-deficient mice (Cftr
MHH) were removed, fixed 
in 4% paraformaldehyde and stained with Cy3-coupled anti-ceramide antibodies. The sections were analysed by fluorescence microscopy. 
The fluorescence intensity represents the concentration of ceramide in epithelial cells. Printed with permission of Nature Medicine [11]. 
 
Fig. (2). Effects of ceramide in cystic fibrosis. Alkalinization of intracellular vesicles, most likely secretory lysosomes, in CF-cells results 
in an imbalance of the activities of the acid sphingomyelinase and the acid ceramidase. The increase of the intravesicular pH to 
approximately pH 6 reduces the activity of the acid sphingomyelinase, which releases ceramide from sphingomyelin, by only 30-40%, while 
the activity of the acid ceramidase, which consumes ceramide, is reduced by more than 90%. Ceramide may then accumulate in CF cells as 
the net effect of the pH-mediated imbalance between the acid sphingomyelinase and the acid ceramidase. Ceramide induces cell death with 
subsequent deposition of DNA in the airways, chronic inflammation as indicated by accumulation of neutrophils, macrophages and pro-
inflammatory cytokines such as Interleukin 1 and 8 in lung tissues and high susceptibility to P. aeruginosa infections. Genetic or 
pharmacological inhibition of the acid sphingomyelinase normalizes pulmonary ceramide, cell death, inflammation and infection 
susceptibility. 
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normalization of pulmonary ceramide concentrations upon 
treatment of cystic fibrosis mice with amitripytline or 
induced by acid sphingomyelinase heterozygosis in Cftr
-/-
/Smpd1
+/- mice does not only prevent increased cell death 
and DNA deposition, but also normalizes the increased 
susceptibility of these mice to P. aeruginosa infections. 
Likewise, inhalation of DNase or inhibitors of the acid 
sphingomyelinase, respectively, reduces DNA-deposits in 
lungs of cystic fibrosis mice and prevents infection with P. 
aeruginosa [11, 82]. This suggests an important role of 
DNA-deposits in the airways of cystic fibrosis mice for the 
development of the high infection susceptibility of these 
mice to P. aeruginosa. 
  It is important to note that pulmonary inflammation 
elicited by ceramide in the respiratory tissue of Cftr-deficient 
mice preceed any bacterial infection. Again, partial 
inhibition of the acid sphingomyelinase by application of 
amitriptyline or in Cftr
-/-/Smpd1
+/- mice reduces the 
concentration of inflammatory cytokines in the lung and 
abrogates the accumulation of neutrophils and macrophages 
indicating the critical role of ceramide for the development 
of chronic inflammation in cystic fibrosis. Many lung 
functions are negatively affected by chronic inflammation, 
which may lead to a reduction of mucociliary clearance, 
local immune response and alterations of the airway 
architecture possibly resulting in pulmonary fibrosis. 
  At present it is unknown how increased ceramide 
concentrations mediate the upregulation of pro-inflammatory 
mediators and the accumulation of neutrophils and 
macrophages in the lung. It might be possible that enhanced 
cell turn over and induction of necrotic cell death trigger 
inflammation. However, it is also possible that other 
mechanisms such as increased expression of cytokines, 
alterations of cell migration, induced expression of adhesion 
molecules on endothelial cells to attract neutrophils and 
macrophages, etc. are important for these effects of 
ceramide. 
  Sphingolipids, in particular sphingomyelin, were recently 
shown to be a component of pulmonary surfactant [83]. 
Whether the alterations of pulmonary ceramide also affect 
surfactant in cystic fibrosis patients is presently unknown. A 
first hint pointing in this direction is the observation that 
local instillation of TNF impairs surfactant functions and 
production that correlates with increased alveolar 
sphingomyelin levels, sphingomyelinase activity and 
possibly also ceramide concentrations [84]. 
  In addition, the role of ceramide in the development of 
fibrosis, which is one of the major problems of children with 
cystic fibrosis, remains to be determined. Fibrosis does not 
seem to be a simple consequence of chronic infection, since 
fibrosis also occurs in Cftr-deficient mice without infection. 
It will be of great interest to investigate whether recent data 
that show a central role of ceramide for the development of 
fibrosis in chronic obstructive pulmonary disease also apply 
for cystic fibrosis. 
P. AERUGINOSA INFECTIONS AND CERAMIDE 
  Previous studies published by our group indicate that P. 
aeruginosa infection of epithelial cells and macrophages 
activates the acid sphingomyelinase and triggers a 
translocation of the enzyme onto the extracellular leaflet of 
the cell membrane [19, 20]. The activity of the acid 
sphingomyelinase triggers the formation of ceramide-
enriched membrane platforms in the outer leaflet. Activation 
of the acid sphingomyelinase is mediated by reactive oxygen 
species, at least in macrophages [20]. Recent studies 
demonstrate that activation of the acid sphingomyelinase is 
defective in cells lacking Cftr [85]. This defect might be 
caused by the altered pH in intracellular vesicles in Cftr-
deficient cells, although the cause for the failure of P. 
aeruginosa to trigger acid sphingomyelinase and ceramide in 
Cftr-deficient cells remains to be determined. Ceramide-
enriched membrane domains might serve the clustering of 
receptors, for instance CD95 and Cftr [19]. Genetic 
deficiency of the acid sphingomyelinase or disruption of 
rafts by interference with cellular cholesterol prevents 
formation of ceramide-enriched membrane platforms, 
internalisation of the bacteria and induction of apoptosis in 
epithelial cells upon infection with P. aeruginosa, but results 
in an uncontrolled cytokine release [19]. The mechanisms 
that mediate an uncontrolled release of cytokines in the lung 
of  Smpd1-deficient mice infected with P. aeruginosa are 
presently not known. 
  Acute pulmonary infection of Smpd1-deficient mice with 
P. aeruginosa reveal that these mice are unable to remove 
the bacteria upon primary lung infection and a high 
percentage of the mice succumbed by a sepsis within a few 
days, while wild type mice are resistant [19]. These findings 
indicate that ceramide is required for the removal of the 
bacteria in the lung, at least during an acute infection. These 
data seem to be contradictory to the results discussed above 
in cystic fibrosis mice, since both, a defect to respond to the 
infection with an activation of the acid sphingomyelinase 
and a release of ceramide as well as a chronic over-
production of ceramide negatively affect the capability of the 
lung to deal with P. aeruginosa. However, this situation 
seems to be typical for many important biological processes. 
For instance, an increased coagulation might result in 
infarcts, while a defect of blood coagulation results in 
spontaneous bleedings. Thus, only a moderate, therapeutic 
inhibition of blood coagulation suppresses infarcts and at the 
same time prevents bleedings. Further, the two situations are 
very different, since Smpd1
-/- mice are unable to remove the 
bacteria from the lung once the infection has been 
established, while the initial number of bacteria in the lung 
of these mice does not differ from that in wildtype mice 
immediately after infection. In contrast, Cftr-deficient mice 
suffer from a defect in the early phase of the infection 
period, i.e. high numbers of bacteria reach the lung or are 
able to remain in the lung immediately after infection. The 
increased susceptibility to develop P. aeruginosa infections 
might be caused by induction of cell death and DNA 
depositions in bronchi that serve the adhesion of the bacteria 
[11]. The therapeutic implications of these considerations are 
discussed below. 
INHIBITION OF THE ACID SPHINGOMYELINASE 
BY SMALL MOLECULE DRUGS TO TREAT CYSTIC 
FIBROSIS 
  The studies in mice indicate that increased ceramide 
concentrations are deleterious for cystic fibrosis patients and 
reduction of ceramide levels by targeting the acid 
sphingomyelinase might be beneficial. However, ceramide Ceramide in Cystic Fibrosis  The Open Respiratory Medicine Journal, 2010, Volume 4    45 
concentrations should not be reduced under a critical cellular 
level by any drug to preserve the biological functions of 
ceramide. Unpublished studies from our group demonstrate 
that already 5-15% residual activity of the acid 
sphingomyelinase permitted a normal response of epithelial 
cells to P. aeruginosa infection. Therefore, treatment with 
amitriptyline in doses that mediate an inhibition of 50-70% 
of the acid sphingomyelinase activity seems to be very safe 
and, at the same time, sufficient to normalize ceramide levels 
(5 pmol/μg lung protein) in cystic fibrosis (Fig. 3). 
  Recently, results from a first randomised, double-blinded, 
placebo-controlled, cross-over pilot study on 4 adult CF 
patients and a phase IIa study on 19 adult CF patients were 
published [86]. These studies revealed that amitripytline is 
safe in patients with cystic fibrosis. They further demonstrate 
that even low doses of amitriptyline significantly increased 
lung functions in cystic fibrosis patients, which was 
measured as forced expiratory volume in the first second 
(FEV1). Finally, ceramide levels determined in respiratory 
epithelial cells from cystic fibrosis patients decreased 
significantly under amitriptyline therapy. Although the 
number of patients tested in these studies is still low, these 
data suggest amitriptyline and related substances as a novel 
therapeutic option in patients with cystic fibrosis. 
  However, these studies were performed with systemic 
application of amitriptyline, which results in some side 
effects, for instance dry mouth or tiredness [86]. Thus, an 
inhalation of the drugs will be definitely preferred over a 
systemic application to achieve higher local doses and, at the 
same time, to avoid any systemic effect. The latter applies in 
particular for treatment of children and for any long-term 
use. The inhalative application of drugs that inhibit the acid 
sphingomyelinase and locally reduce ceramide in lungs of 
cystic fibrosis patients must be developed and tested. 
However, the above-described studies in mice and first 
clinical data already identified this group of small molecules 
as potential drugs to treat cystic fibrosis and justify further 
development of these small molecule drugs. 
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